Rivera, José Carlos
Holm, Mari
Austeng, Dordi
Morken, Tora Sund
Zhou, Tianwei (Ellen)
Beaudry-Richard, Alexandra
Sierra, Estefania Marin
Dammann, Olaf
Chemtob, Sylvain
Funding for this research was provided by:
Canada Research Chairs
Canadian Institutes of Health Research
Leopoldine Wolfe Chair in Translational Research
March of Dimes Canada
National Institutes of Health
Article History
Received: 25 February 2017
Accepted: 14 August 2017
First Online: 22 August 2017
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: The corresponding author (SC) holds a patent on a small peptide antagonist of IL-1 receptor, which could be useful in inflammatory ischemic retinopathies; yet, this compound remains at pre-clinical stage and the intellectual property is held by the CHU Ste. Justine, Montreal. Hence the competing interests are at best questionable.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.